Bayer Q3 sales, EBITDA beat estimates; raises 2026 earnings and cash flow outlook

What happened: Bayer raised its 2026 earnings and cash flow outlook after third-quarter sales and EBITDA beat analyst expectations, led by growth in its pharmaceuticals division. Key numbers: Q3 sales rose 4.1% to €10.05 billion, beating the €9.92 billion Why it matters: The pharmaceuticals division drove the beat, with sales up 8% and EBITDA before special items up 23.6%. Chief Executive Bill Anderson said the division had reached a turning point in its growth trajectory, and the CFO cited year-to-date performance as the basis for raising full-year earnings, cash flow and debt targets. Coverage: 3 outlets in 24h

Bayer raised its 2026 earnings and cash flow outlook after third-quarter sales and EBITDA beat analyst expectations, led by growth in its pharmaceuticals division.

The pharmaceuticals division drove the beat, with sales up 8% and EBITDA before special items up 23.6%. Chief Executive Bill Anderson said the division had reached a turning point in its growth trajectory, and the CFO cited year-to-date performance as the basis for raising full-year earnings, cash flow and debt targets.